Common risk-reducing strategies for BRCA mutation carriers and timing.

• A. No risk reduction
• B. Bilateral mastectomy and/or salpingo-oophorectomy; timing individualized based on age, fertility plans, and gene-specific cancer risks
• C. Surveillance only
• D. Chemoprevention only

Answer: (B)

Risk-reducing management for BRCA mutation carriers relies on proactive surgical interventions that dramatically lower cancer risk, with the timing tailored to the person’s age, fertility goals, and gene-specific risk profile. Bilateral mastectomy can substantially cut breast cancer risk, while salpingo-oophorectomy (removal of the ovaries and fallopian tubes) dramatically lowers ovarian cancer risk and also reduces breast cancer risk in premenopausal carriers by reducing ovarian hormone exposure. Because BRCA1 and BRCA2 carry different cancer risk patterns and onset ages, the timing of these procedures is individualized: mastectomy can be pursued when someone chooses, often after childbearing, and oophorectomy is typically considered in the 30s to 40s for BRCA1 and around the 40s for BRCA2, with the exact timing discussed based on personal circumstances and gene-specific risks. Surveillance and chemoprevention play roles in risk management, but they do not achieve the same level of risk reduction as these surgical options, which is why the combined approach of surgery with individualized timing represents the most effective strategy for many BRCA carriers.